FDA Recommends Study Designs for BE Studies With Pharmacokinetic Endpoints

Drug Industry Daily
In an effort to head off one of the most common problems that sidetracks ANDA submissions, the FDA is telling drugmakers that bioequivalence studies for most drugs submitted as ANDAs should use a two-period, two-sequence, single-dose, crossover study design.

To View This Article:


Subscribe To Drug Industry Daily